<DOC>
	<DOCNO>NCT02253836</DOCNO>
	<brief_summary>Study investigate effect steady-state TPV/r ( 500 mg/100 mg BID ) single-dose steady-state pharmacokinetics Atazanavir ( 300 mg QD ) co-administered Ritonavir ( 100 mg ) . To investigate effect single-dose steady-state Atazanavir ( 300 mg ) steady-state pharmacokinetics Tipranavir Ritonavir .</brief_summary>
	<brief_title>Pharmacokinetic Study Healthy Adult Volunteers Assess Interactions Between Steady-State Tipranavir Atazanavir Presence Ritonavir</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria>1 . Male female subject 18 60 year age inclusive 2 . A Body Mass Index ( BMI ) 18 29 kg/m2 3 . Signed informed consent prior trial participation 4 . Ability swallow multiple large capsule without difficulty 5 . Acceptable laboratory value indicate adequate baseline organ function screen visit : Laboratory value consider acceptable severity parameter â‰¤ Grade 1 , base Division AIDS/AIDS Clinical Trials Group Grading Scale All abnormal laboratory value &gt; Grade 1 subject approval trial clinical monitor 6 . Acceptable medical history , physical examination , 12lead ECG screen 7 . Willingness abstain follow start 2 week prior administration study medication end study : Grapefruit grapefruit juice , Red wine , Seville oranges , St. John 's Wort , Milk Thistle 8 . Willingness abstain alcohol start 3 day prior administration study medication end study 9 . Willingness abstain follow start 3 day prior pharmacokinetic ( PK ) sampling : Garlic supplement Methylxanthine contain food drink ( include coffee , tea , cola , energy drink , chocolate , etc . ) 10 . Willingness abstain overthecounter herbal medication duration study 11 . Must nonsmoker 12 . Willingness abstain vigorous physical exercise intensive PK Days 1 , 9 , 23 , 24 32 13 . Reasonable probability completion study 1 . Female subject reproductive potential : Have positive serum pregnancy test Have use barrier method contraception least 3 month prior participation study Are willing use reliable method barrier contraception ( diaphragm spermicidal cream/jelly condoms spermicidal foam ) , 60 day completion/termination trial Are breastfeed 2 . Participation another trial investigational medicine within 2 month prior Day 0 study 3 . Use medication list protocol within 30 day prior Day 0 study 4 . Use pharmacological contraceptive ( include oral , patch injectable contraceptive ) within 1 month prior Day 0 duration study . Due long halflife , subject use DepoProvera within six month prior Day 0 exclude participation study 5 . Use hormone replacement therapy within 1 month prior Day 0 anytime study 6 . Administration antibiotic within 15 day prior Day 0 anytime study 7 . History acute illness within 60 day prior Day 0 Subjects exclude acute illness occur 60 day prior Day 0 , opinion investigator , subject qualify healthy volunteer 8 . Have serological evidence hepatitis B C virus 9 . Have serological evidence exposure HIV 10 . Alcohol substance abuse within 1 year prior screen study 11 . Blood plasma donation within 30 day prior Day 0 study 12 . Subjects history illness allergy , opinion investigator , might confound result study pose additional risk administer Tipranavir , Ritonavir Atazanavir subject 13 . Subjects preexist heart conduction abnormalities 14 . Subjects take ( within 7 day prior Day 0 ) overthecounter prescription medication , opinion investigator consultation clinical monitor , might interfere absorption , distribution , metabolism study medication 15 . Known hypersensitivity sulphonamide class drug 16 . Inability adhere protocol 17 . Cautions warning Ritonavir Atazanavir package insert , opinion investigator , constitute ground subject exclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>